Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mysimba for weight optimization after bariatric surgery
NCT04399395Phase 4Withdrawn
- Sponsor
- Oslo University Hospital
- Start
- Nov 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of naltrexone + bupropion in obesity (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Body weight at 7 months. Planned start Nov 2020; status: withdrawn.
02
Drugs
naltrexone + bupropion
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04399395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04399395.